BRPI0518484A2 - composiÇço, cÁpsula, e, processo para preparar a mesma - Google Patents

composiÇço, cÁpsula, e, processo para preparar a mesma

Info

Publication number
BRPI0518484A2
BRPI0518484A2 BRPI0518484-3A BRPI0518484A BRPI0518484A2 BR PI0518484 A2 BRPI0518484 A2 BR PI0518484A2 BR PI0518484 A BRPI0518484 A BR PI0518484A BR PI0518484 A2 BRPI0518484 A2 BR PI0518484A2
Authority
BR
Brazil
Prior art keywords
capsule
composition
surfactant
hlb
preparing same
Prior art date
Application number
BRPI0518484-3A
Other languages
English (en)
Inventor
Andrey V Peresypkin
Eleni Dokou
Craig Mckelvey
Charles Deluca
Laman L Alani
Todd Gibson
Danielle H Euler
Santipharp Panmai
W Peter Wuelfing
Thomas P Gandek
Drazen Ostovic
Timothy Rhodes
Brian K Hamilton
Original Assignee
Merck & Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck & Co Inc filed Critical Merck & Co Inc
Publication of BRPI0518484A2 publication Critical patent/BRPI0518484A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10—Laxatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Addiction (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Pulmonology (AREA)
  • Dispersion Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Hospice & Palliative Care (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Psychology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

COMPOSIÇçO, CÁPSULA, E, PROCESSO PARA PREPARAR A MESMA. A N- [1S,2S]-3 -(4-clorofenil)-2-(3 -cianofenil)- 1 -metilpropil] - 2-metil-2- { [5 -trifluorometil]piridina-2-il } áxi } propanamida (Composto 1) melhorou surpreendentemente a solubilidade e a biodisponibilidade em um veículo lipofilico que compreende um óleo digerivel, farmaceuticamente aceitável, um tensoativo ou, um co-solvente ou, uma mistura de quaisquer de dois ou mais destes. Em uma forma de realização da presente invenção existe composições auto-emulsificantes ou auto-microemulsificantes que compreendem 1) Composto 1; 2) um tensoativo que tem um HLB de 1 a 8; e 3) um tensoativo que tem um HLB de mais de 8 a 20; e opcionalmente, 4) um óleo digerivel e/ou co-solvente e/ou antioxidante ou conservante.
BRPI0518484-3A 2004-11-24 2005-11-18 composiÇço, cÁpsula, e, processo para preparar a mesma BRPI0518484A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US63074604P 2004-11-24 2004-11-24
PCT/US2005/041836 WO2006057903A2 (en) 2004-11-24 2005-11-18 Liquid and semi-solid pharmaceutical formulations for oral administration of a substituted amide

Publications (1)

Publication Number Publication Date
BRPI0518484A2 true BRPI0518484A2 (pt) 2008-11-18

Family

ID=36498432

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0518484-3A BRPI0518484A2 (pt) 2004-11-24 2005-11-18 composiÇço, cÁpsula, e, processo para preparar a mesma

Country Status (14)

Country Link
US (1) US20070298099A1 (pt)
EP (1) EP1817012A2 (pt)
JP (1) JP2008521807A (pt)
KR (1) KR20070084531A (pt)
CN (1) CN101065115A (pt)
AU (1) AU2005309808A1 (pt)
BR (1) BRPI0518484A2 (pt)
CA (1) CA2587733A1 (pt)
IL (1) IL183309A0 (pt)
MX (1) MX2007006183A (pt)
NO (1) NO20073224L (pt)
RU (1) RU2007123366A (pt)
WO (1) WO2006057903A2 (pt)
ZA (1) ZA200703532B (pt)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20160184258A1 (en) * 2005-11-07 2016-06-30 Murty Pharmaceuticals, Inc. Oral gastrointestinal dosage form delivery system of cannabinoids and/or standardized marijuana extracts
US9265724B2 (en) * 2005-11-07 2016-02-23 Ram B. Murty Oral dosage form of tetrahydrocannabinol and a method of avoiding and/or suppressing hepatic first pass metabolism via targeted chylomicron/lipoprotein delivery
AU2016203127B2 (en) * 2005-11-07 2018-07-12 Murty Pharmaceuticals, Inc An improved oral gastrointestinal dosage form delivery system of cannabinoids and/or standardized marijuana extracts
MY153288A (en) * 2006-06-28 2015-01-29 Hovid Berhad An effective pharmaceutical carrier for poorly bioavailable drugs
US20100209496A1 (en) * 2006-09-06 2010-08-19 Eleni Dokou Liquid and semi-solid pharmaceutical formulations for oral administration of a substituted amide
US20090041839A1 (en) * 2007-05-23 2009-02-12 Beasley Martin W Pharmaceutical compositions for the treatment of pain
JP5576279B2 (ja) * 2007-08-21 2014-08-20 バジリア ファルマスーチカ アーゲー 抗真菌組成物
PL2268160T3 (pl) * 2008-03-20 2013-05-31 Virun Inc Emulsje zawierające pochodną PEG tokoferolu
BRPI0909185A2 (pt) 2008-03-20 2015-08-25 Virun Inc Derivado de vitamina e e seus usos
EP2111854A1 (en) * 2008-04-22 2009-10-28 Lek Pharmaceuticals D.D. Self-microemulsifying systems incorporated into liquid core microcapsules
US8026271B2 (en) * 2008-07-11 2011-09-27 National Health Research Institutes Formulations of indol-3-yl-2-oxoacetamide compounds
US20100041622A1 (en) * 2008-08-13 2010-02-18 Bromley Philip J Compositions containing aminoalkanes and aminoalkane derivatives
WO2010044093A1 (en) * 2008-10-16 2010-04-22 Strides Arcolab Limited Formulations containing rifaximin
US20110082205A1 (en) * 2009-10-01 2011-04-07 Panker Cynthia A Docosahexaenoic Acid Gel Caps
CA2690490C (en) * 2010-01-19 2012-06-26 Accucaps Industries Limited Pharmaceutical formulations of loratadine for encapsulation and combinations thereof
CA2792330C (en) 2010-03-23 2017-01-03 Virun, Inc Nanoemulsion including a peg-derivative of vitamin e and a sucrose fatty acid ester
WO2011162802A1 (en) 2010-06-21 2011-12-29 Virun, Inc. Compositions containing non-polar compounds
JP2013209294A (ja) * 2010-07-30 2013-10-10 Ｍｅｉｊｉ Ｓｅｉｋａファルマ株式会社 液状医薬組成物
EP2438911A1 (en) * 2010-10-08 2012-04-11 LEK Pharmaceuticals d.d. Pharmaceuticals compositions comprising sulphonylurea-class insulin secretagogue and polyethylene glycol castor oil
US9504664B2 (en) 2010-10-29 2016-11-29 Infirst Healthcare Limited Compositions and methods for treating severe pain
US10695432B2 (en) 2010-10-29 2020-06-30 Infirst Healthcare Limited Solid solution compositions and use in severe pain
US10695431B2 (en) 2010-10-29 2020-06-30 Infirst Healthcare Limited Solid solution compositions and use in cardiovascular disease
US11730709B2 (en) 2010-10-29 2023-08-22 Infirst Healthcare Limited Compositions and methods for treating severe pain
US9308213B2 (en) 2010-10-29 2016-04-12 Infirst Healthcare Limited Solid solution compositions and use in chronic inflammation
US11202831B2 (en) 2010-10-29 2021-12-21 Infirst Healthcare Limited Solid solution compositions and use in cardiovascular disease
US9271950B2 (en) 2010-10-29 2016-03-01 Infirst Healthcare Limited Compositions for treating chronic inflammation and inflammatory diseases
US9744132B2 (en) 2010-10-29 2017-08-29 Infirst Healthcare Limited Solid solution compositions and use in chronic inflammation
US8895537B2 (en) 2010-10-29 2014-11-25 Infirst Healthcare Ltd. Compositions and methods for treating cardiovascular diseases
US11224659B2 (en) * 2010-10-29 2022-01-18 Infirst Healthcare Limited Solid solution compositions and use in severe pain
TW202446781A (zh) 2011-12-28 2024-12-01 日商中外製藥股份有限公司 胜肽化合物之製造方法
US10874122B2 (en) 2012-02-10 2020-12-29 Virun, Inc. Beverage compositions containing non-polar compounds
EP2943183A1 (en) * 2013-01-14 2015-11-18 InFirst Healthcare Limited Compositions and methods for treating severe pain
KR102235264B1 (ko) * 2013-01-14 2021-04-02 인퍼스트 헬스케어 리미티드 고용체 조성물들 및 심각한 통증에서의 이들의 용도
CA2898017A1 (en) * 2013-02-04 2014-08-07 Infirst Healthcare Limited Compositions and methods for treating chronic inflammation and inflammatory diseases
US9351517B2 (en) 2013-03-15 2016-05-31 Virun, Inc. Formulations of water-soluble derivatives of vitamin E and compositions containing same
WO2015193224A1 (en) * 2014-06-17 2015-12-23 Merck Sharp & Dohme B.V. Stable formulations of testosterone undecanoate
EP3280398B1 (en) 2015-04-10 2026-02-25 Bioresponse LLC Self-emulsifying formulations of dim-related indoles
US10722527B2 (en) * 2015-04-10 2020-07-28 Capsugel Belgium Nv Abiraterone acetate lipid formulations
JP7173870B2 (ja) * 2016-12-28 2022-11-16 中外製薬株式会社 化合物の膜透過性を改善するための自己乳化型製剤
MX390102B (es) * 2017-02-07 2025-03-20 Rhein Siegfried Sa De Cv Composicion de liberacion rapida de cinitaprida y simeticona y proceso para prepararla.
WO2018219804A1 (en) * 2017-06-02 2018-12-06 Bayer Pharma Aktiengesellschaft Self-microemulsifying drug delivery systems
WO2020112961A1 (en) * 2018-11-30 2020-06-04 Chemocentryx, Inc. Capsule formulations
EP3952900A1 (en) 2019-04-11 2022-02-16 R.P. Scherer Technologies, LLC Formulation for oral delivery of proteins, peptides and small molecules with poor permeability
WO2022251709A1 (en) * 2021-05-28 2022-12-01 Natural Extraction Systems, LLC Bioactive biphasic compositions
US20260102403A1 (en) * 2024-10-11 2026-04-16 Aligos Therapeutics, Inc. Oral formulations of thr-beta agonist

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9405304D0 (en) * 1994-03-16 1994-04-27 Scherer Ltd R P Delivery systems for hydrophobic drugs
FR2761266B1 (fr) * 1997-03-28 1999-07-02 Sanofi Sa Composition pharmaceutique formee par granulation humide pour l'administration orale d'un derive du n-piperidino-3- pyrazolecarboxamide, de ses sels et de leurs solvates
US6638522B1 (en) * 1998-12-11 2003-10-28 Pharmasolutions, Inc. Microemulsion concentrate composition of cyclosporin
JP2000256323A (ja) * 1999-01-08 2000-09-19 Japan Tobacco Inc ２−オキソキノリン化合物及びその医薬用途
US6294192B1 (en) * 1999-02-26 2001-09-25 Lipocine, Inc. Triglyceride-free compositions and methods for improved delivery of hydrophobic therapeutic agents
US6383471B1 (en) * 1999-04-06 2002-05-07 Lipocine, Inc. Compositions and methods for improved delivery of ionizable hydrophobic therapeutic agents
US20020102301A1 (en) * 2000-01-13 2002-08-01 Joseph Schwarz Pharmaceutical solid self-emulsifying composition for sustained delivery of biologically active compounds and the process for preparation thereof
FR2804015B1 (fr) * 2000-01-21 2005-12-23 Oreal Nanoemulsion contenant des lipides amphiphiles et un polymere non ionique et utilisations
US6562822B2 (en) * 2000-07-12 2003-05-13 Pharmacia & Upjohn Company Heterocyle carboxamides as antiviral agents
FR2818905A1 (fr) * 2000-12-28 2002-07-05 Cll Pharma Compositions pharmaceutiques colloidales micellaires renfermant un principe actif lipophile
DE10107261B4 (de) * 2001-02-16 2005-03-10 Merck Patent Gmbh Pharmazeutische Zusammensetzung
GB2391471B (en) * 2002-08-02 2005-05-04 Satishchandra Punambhai Patel Pharmaceutical compositions
EP1498122A1 (en) * 2003-07-18 2005-01-19 Aventis Pharma S.A. Semi-solid systems containing azetidine derivatives
US8535716B2 (en) * 2004-04-01 2013-09-17 Tsrl, Inc. Methods and composition of extended delivery of water insoluble drugs
WO2009048544A1 (en) * 2007-10-10 2009-04-16 Merck & Co., Inc. Liquid pharmaceutical compositions for parenteral administration of a substituted amide

Also Published As

Publication number Publication date
NO20073224L (no) 2007-08-23
JP2008521807A (ja) 2008-06-26
RU2007123366A (ru) 2008-12-27
CA2587733A1 (en) 2006-06-01
ZA200703532B (en) 2008-09-25
EP1817012A2 (en) 2007-08-15
WO2006057903A2 (en) 2006-06-01
MX2007006183A (es) 2007-09-11
US20070298099A1 (en) 2007-12-27
WO2006057903A3 (en) 2006-07-20
AU2005309808A1 (en) 2006-06-01
KR20070084531A (ko) 2007-08-24
CN101065115A (zh) 2007-10-31
IL183309A0 (en) 2007-09-20

Similar Documents

Publication Publication Date Title
BRPI0518484A2 (pt) composiÇço, cÁpsula, e, processo para preparar a mesma
KR102656954B1 (ko) 경구용 탁산 조성물 및 방법
US20200222360A1 (en) Stable cannabinoid compositions
MX2022013984A (es) Inhibidores de cinasa 7 relacionada con el gen nunca en mitosis a (nek7).
CY1110261T1 (el) Παραγωγα της κουμαρινης που χρησιμοποιουνται σαν αντιπηκτικα
WO2020089891A1 (en) Topical minocycline foamable compositions
MX2022004735A (es) Composiciones que comprenden compuestos superfinos y su produccion.
AU2003285143A8 (en) Analysis of pharmaceutical solubility and stability
DE60222580D1 (de) Lipidträgerzusammensetzungen und verfahren zur verbesserten wirkstoffzurückhaltung
ATE390924T1 (de) Stabile creme-zubereitungen von phenyl- pyridonverbindungen für topische anwendung
IS7311A (is) Lyfjafræðileg samsetning sem samanstendur af sýklósporíni og notkun á henni
AU2018296679A1 (en) Stable cannabinoid compositions
MY138172A (en) Pharmaceutical compositions based on azetidine derivatives
JP2018517784A (ja) デュタステリドを含有する医薬組成物及びそれを含むカプセル製剤
CA2695605A1 (en) Pyrazolone derivative emulsion formulations
TW201630606A (zh) 包含局部藥物之蓋崙（ｇａｌｅｎｉｃ）調配物
CA2734284C (en) Pyrazolone derivative formulations
JP5778964B2 (ja) 油性製剤
JP7412871B2 (ja) 外用組成物
JP2018052845A (ja) 外用組成物
JP2014516946A (ja) エザチオスタットとの賦形剤適合性
JP7206042B2 (ja) 外用組成物
MY198026A (en) Parenteral nutrition formulation and methods of preparation thereof
AR053333A1 (es) Composiciones farmaceuticas orales y parenterales que contienen altas concentraciones de agentes solubilizantes aromaticos
RU2006115446A (ru) Состав для стабилизации липидов

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE AS 5A E 6A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2160 DE 29/05/2012.